Learn More
Description
The SK11 monoclonal antibody specifically binds to CD62L which is also known as, L-selectin, Leukocyte-endothelial cell adhesion molecule 1 (LECAM1/LECAM-1), Leukocyte adhesion molecule 1 (LAM1/LAM-1), Lymph node homing receptor (LNHR), Leu-8, or TQ1. CD62L is an ∽80 kDa type I transmembrane glycoprotein that belongs to the Selectin/LECAM family. CD62L is differentially expressed on T cells, B cells, monocytes, granulocytes, and a subset of NK cells. The CD62L molecule is the human homolog of the mouse lymph node homing receptor, MEL-14. CD62L plays a role in leucocyte binding to inflamed endothelium and extravasation, as well as mediating lymphocyte homing into peripheral lymphoid tissues through high endothelial postcapillary venules. Soluble CD62L can result from the proteolytic cleavage of cell surface CD62L during cellular activation or inflammation.
The antibody was conjugated to BD Horizon BUV395 which has been exclusively developed by BD Biosciences as an optimal dye for use on a 355nm laser equipped instrument. With an Ex Max at 348nm and an Em Max at 395nm, this dye has virtually no spillover into any other detector. BD Horizon BUV395 can be excited with a 355nm laser and detected with a 379/28 filter.
Specifications
Specifications
| Antigen | CD62L |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | SK11 |
| Conjugate | Brilliant Ultraviolet 395 |
| Description | L-selectin; LECAM-1; SELL; LNHR; LSEL; LAM-1; LEU8; PLNHR; TQ-1; MEL-14 |
| Formulation | Aqueous buffered solution containing BSA and ≤0.09% sodium azide |
| Host Species | Mouse |
| Immunogen | Human Peripheral Blood T Lymphocytes |
| Purification Method | Affinity Purified |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.